Victory Capital Management
ORMP icon

Victory Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Victory Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,704
Closed -$70K – 2735
2022
Q1 		$70K Buy
13,704
+394
+3% +$4.04K ﹤0.01% 2564
2021
Q4 		$190K Buy
+13,310
New +$278K ﹤0.01% 2492
2020
Q2 		– Sell
-6,274
Closed -$20K – 3036
2020
Q1 		$20K Buy
+6,274
New +$27.5K ﹤0.01% 3097
2019
Q4 		– Sell
-2,472
Closed -$8K – 3067
2019
Q3 		$8K Buy
+2,472
New +$8.23K ﹤0.01% 3337

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management's ORMP Position: Q2 2022 in Review

Victory Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 13,704 shares — an estimated $70K sold.

Victory Capital Management first reported a position in ORMP in Q3 2019 and held it in 4 quarters. The position peaked at $190K in Q4 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Victory Capital Management reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Victory Capital Management sold 13,704 Oramed Pharmaceuticals shares in Q2 2022, an estimated $70K.
  • Victory Capital Management first reported a position in Oramed Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Victory Capital Management's Oramed Pharmaceuticals position peaked at $190K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.